These devices are non-invasive, painless, and provide instant results helping in faster diagnosis and treatment planning. Transient elastography helps reduce the need for liver biopsies which are invasive and risky procedures. The growing chronic liver disease burden and scarcity of organs for transplantation is propelling the demand for transient elastography devices globally.

The Global transient elastography devices market is estimated to be valued at US$ 102.68 KT in 2024 and is expected to exhibit a CAGR of 1.9% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the transient elastography devices are Echosens, HISKY Medical Technologies Co., Ltd. and SMEDA Medical Co., Ltd. Echosens dominates the market with its FibroScan device being the gold standard for liver fibrosis assessment across the world.

The growing awareness about liver diseases and advantages of transient elastography over liver biopsy procedures presents lucrative growth opportunities for market players. Transient Elastography Devices Market Demand Major players are investing in R&D to develop novel applications of transient elastography in fatty liver disease assessment and other indications.

The key players are expanding their geographic footprint through partnerships and distribution agreements in emerging markets of Asia Pacific, Latin America, Middle East and Africa. Echosens recently partnered with Max Healthcare to bring FibroScan to India. HISKY Medical also collaborates with regional distributors to service Southeast Asian countries. This global expansion aims to cater to the increasing demand and facilitate access to advanced diagnostic solutions.

Market Drivers and Restraints
Rising geriatric population predisposed to chronic liver ailments due to medical conditions like diabetes and obesity is a major market driver. According to WHO, chronic liver disease is the second most common cause of death due to non-communicable diseases globally. Transient elastography aids in better management of such high-risk patients.

High initial costs of transient elastography devices and need for trained professionals to operate them are significant market restraints. Limited awareness in low and middle-income nations also hampers adoption. However, device manufacturers are making efforts to address these challenges via financing options, training programs, and educational initiatives to promote widespread access and utility of transient elastography worldwide.

Segment Analysis

The transient elastography devices market is dominated by the fibroscan segment. Fibroscan devices offer non-invasive and painless scans to measure liver stiffness and detect advanced liver fibrosis or cirrhosis. Fibroscan can quantify the degree of liver fibrosis and also detect its stage before the appearance of clinical symptoms. It has wide acceptance among healthcare professionals and patients due to its repeatability and accuracy. The devices are easy to use and interpret, and results are available immediately, making fibroscan suitable for primary screening of fibrosis in patients with chronic liver disease.

Global Analysis

The Asia Pacific region is poised to witness the fastest growth in the transient elastography devices market during the forecast period. This is majorly attributed to the growing prevalence of hepatitis B and C infections in Asian countries such as China, India and Japan. Increasing healthcare expenditure, rising awareness about liver diseases, and improving access to advanced diagnostic technologies are some key factors driving the adoption of transient elastography devices in Asia Pacific. Moreover, the presence of leading local manufacturers such as HISKY Medical Technologies and SMEDA Medical is contributing to market growth in the region. North America and Europe will continue to dominate the global market supported by established healthcare systems and availability of reimbursement for elastography procedures.
​
Get more insights on This Topic- Transient Elastography Devices Market